Amol Akhade/LinkedIn
Apr 30, 2025, 08:50
Updates from AACR25 by Amol Akhade
Amol Akhade, Consultant Medical Oncologist and Hemato-oncologist at Suyog Cancer Clinics, shared an updates from AACR25 on X:
“Exciting update from AACR25!
Combo of Botensilimab + Balstilimab in neoadjuvant setting:
pMMR tumors: 70% MPR
dMMR tumors: 80% MPR, 70% pCR
Low-grade irAEs and no surgical delays!
Organ preservation possible
High response even in ‘cold’ tumors like UPS, ER+BC, TNBC!
Promising step for neoadjuvant immunotherapy”
BIG NEWS at AACR25
“Aumolertinib + Chemo for metastatic EGFR+ NSCLC!
Median PFS: 28.9 vs 18.9 months (HR 0.47)
Early OS trend: HR 0.44
Strong across all subgroups — gender, CNS mets, EGFR mutations
Especially powerful in young, smokers, Ex19del patients!
CNS control preserved!
Compared to Osimertinib+Chemo (FLAURA2):
Higher PFS
Better HRs across key groups
Could Aumolertinib + Chemo redefine EGFR NSCLC management? Or another Me Too combination?
Time will tell!
We need more global data and off course toxicity data”
More posts featuring AACR25
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 21, 2025, 21:13
May 21, 2025, 19:10
May 21, 2025, 18:49
May 21, 2025, 18:11
May 21, 2025, 18:05
May 21, 2025, 18:02